MedTrace Logo

A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

NCT07403188 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-02-11

No results posted yet for this study

Summary

The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product).

This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).

Conditions

  • Refractory Lupus Nephritis
  • Myasthaenia Gravis
  • Stiff Person Syndrome
  • Rheumatoid Arthritis (RA)
  • Multiple Sclerosis
  • Dermatomyositis
  • Systemic Sclerosis (SSc)

Interventions

DRUG

KYV-101

Autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) product.

Sponsors & Collaborators

  • Kyverna Therapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2041-01-31
Completion
2041-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07403188 on ClinicalTrials.gov